Pio M Furneri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8034736/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bacteriocins, A Natural Weapon Against Bacterial Contamination for Greater Safety and Preservation of Food: A Review. Current Pharmaceutical Biotechnology, 2021, 22, 216-231.	0.9	7
2	Investigation on the Antibacterial Activity of Electronic Cigarette Liquids (ECLs): A Proof of Concept Study. Current Pharmaceutical Biotechnology, 2021, 22, 983-994.	0.9	3
3	Natural Substances in the Fight of SARS-CoV-2: A Critical Evaluation Resulting from the Cross-Fertilization of Molecular Modeling Data with the Pharmacological Aspects. Current Medicinal Chemistry, 2021, 28, 8333-8383.	1.2	5
4	Natural Substances and Semisynthetic Derivatives as Potential Alternative Products Against SARS-CoV-2. Mini-Reviews in Medicinal Chemistry, 2021, 21, 1596-1611.	1.1	2
5	Lactobacillus rhamnosus AD3 as a Promising Alternative for Probiotic Products. Biomolecules, 2021, 11, 94.	1.8	13
6	Dual-drugs delivery in solid lipid nanoparticles for the treatment of Candida albicans mycosis. Colloids and Surfaces B: Biointerfaces, 2020, 186, 110705.	2.5	45
7	New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine. International Journal of Molecular Sciences, 2020, 21, 5856.	1.8	25
8	Metabolic Characterization of Supernatants Produced by Lactobacillus spp. With in vitro Anti-Legionella Activity. Frontiers in Microbiology, 2019, 10, 1403.	1.5	30
9	Biological properties and production of bacteriocinsâ€likeâ€inhibitory substances by <i>Lactobacillus</i> sp. strains from human vagina. Journal of Applied Microbiology, 2019, 126, 1541-1550.	1.4	39
10	Antioxidant and antimicrobial properties of <i>Casteanea sativa Miller</i> chestnut honey produced on Mount Etna (Sicily). Natural Product Research, 2019, 33, 843-850.	1.0	20
11	Lipid Nanoparticles and Active Natural Compounds: A Perfect Combination for Pharmaceutical Applications. Current Medicinal Chemistry, 2019, 26, 4681-4696.	1.2	19
12	Biological properties of Cakile maritima Scop. (Brassicaceae) extracts. European Review for Medical and Pharmacological Sciences, 2019, 23, 2280-2292.	0.5	8
13	Repurposing itraconazole to the benefit of skin cancer treatment: A combined azole-DDAB nanoencapsulation strategy. Colloids and Surfaces B: Biointerfaces, 2018, 167, 337-344.	2.5	27
14	Commentary: Inflammatory and Oxidative Responses Induced by Exposure to Commonly Used e-Cigarette Flavoring Chemicals and Flavored e-Liquids without Nicotine. Frontiers in Physiology, 2018, 9, 1240.	1.3	1
15	Electronic cigarette vapour enhances pneumococcal adherence to airway epithelial cells under abnormal conditions of exposure. European Respiratory Journal, 2018, 52, 1800915.	3.1	0
16	A Method for Efficient Loading of Ciprofloxacin Hydrochloride in Cationic Solid Lipid Nanoparticles: Formulation and Microbiological Evaluation. Nanomaterials, 2018, 8, 304.	1.9	40
17	Lipid-based Nanosized Delivery Systems for Fluoroquinolones: A Review. Current Pharmaceutical Design, 2018, 23, 6696-6704.	0.9	12

18 Nanosized devices as antibiotics and antifungals delivery: past, news, and outlook. , 2017, , 697-748.

#	Article	IF	CITATIONS
19	Antimicrobial and Anti-Proliferative Effects of Skin Mucus Derived from Dasyatis pastinaca (Linnaeus,) Tj ETQq1	1 0,784314 2.2	rgBT /Over
20	Commentary: Lactobacilli Dominance and Vaginal pH: Why Is the Human Vaginal Microbiome Unique?. Frontiers in Microbiology, 2017, 8, 1815.	1.5	13
21	Probiotic Properties of Lactobacillus fermentum Strains Isolated from Human Oral Samples and Description of their Antibacterial Activity. Current Pharmaceutical Biotechnology, 2017, 18, 138-149.	0.9	23
22	Synthesis, characterization and inÂvitro evaluation of amphiphilic ion pairs of erythromycin and kanamycin antibiotics with liposaccharides. European Journal of Medicinal Chemistry, 2016, 120, 329-337.	2.6	6
23	Labeling quality and molecular characterization studies of products containing Lactobacillus spp. strains International Journal of Immunopathology and Pharmacology, 2016, 29, 121-128.	1.0	10
24	Key Roles of Human Polymorphonuclear Cells and Ciprofloxacin in Lactobacillus Species Infection Control. Antimicrobial Agents and Chemotherapy, 2016, 60, 1638-1641.	1.4	8
25	Growth and adhesion to HT-29 cells inhibition of Gram-negatives by Bifidobacterium longum BB536 e Lactobacillus rhamnosus HN001 alone and in combination. European Review for Medical and Pharmacological Sciences, 2016, 20, 4943-4949.	0.5	18
26	Evaluation of resistance to low pH and bile salts of human Lactobacillus spp. isolates. International Journal of Immunopathology and Pharmacology, 2015, 28, 426-433.	1.0	35
27	Preparation and Microbiological Evaluation of Amphiphilic Kanamycin-Lipoamino Acid Ion-Pairs. Antibiotics, 2014, 3, 216-232.	1.5	4
28	Anti-Adhesion Activity of A2-type Proanthocyanidins (a Cranberry Major Component) on Uropathogenic E. coli and P. mirabilis Strains. Antibiotics, 2014, 3, 143-154.	1.5	36
29	InÂvitro antimycoplasmal activity of citrus bergamia essential oil and its major components. European Journal of Medicinal Chemistry, 2012, 52, 66-69.	2.6	45
30	Amphiphilic Erythromycin-Lipoamino Acid Ion Pairs: Characterization and In Vitro Microbiological Evaluation. AAPS PharmSciTech, 2011, 12, 468-475.	1.5	16
31	Amphiphilic ion pairs of tobramycin with lipoamino acids. European Journal of Medicinal Chemistry, 2011, 46, 1665-1671.	2.6	17
32	<i>In Vitro</i> Activity of Cefditoren <i>versus</i> other Antibiotics against <i>S. Pneumoniae</i> Clinical Strains Isolated in Italy. International Journal of Immunopathology and Pharmacology, 2010, 23, 833-840.	1.0	4
33	Synergism and postantibiotic effect of tobramycin and Melaleuca alternifolia (tea tree) oil against Staphylococcus aureus and Escherichia coli. Phytomedicine, 2010, 17, 317-322.	2.3	115
34	Antimycoplasmal Activity of Oleuropein. , 2010, , 1355-1361.		0
35	Antibiotic Susceptibility of Respiratory Pathogens Recently Isolated in Italy: Focus on Cefditoren. Journal of Chemotherapy, 2010, 22, 153-159.	0.7	11

Usage of Hydroxytyrosol for Antimycoplasmal Activity. , 2010, , 1283-1288.

1

#	Article	IF	CITATIONS
37	Management of Aerobic Vaginitis. Gynecologic and Obstetric Investigation, 2010, 70, 244-249.	0.7	42
38	<i>In Vitro</i> Evaluation of the Synergistic Activity of Neomycin-Polymyxin B Association against Pathogens Responsible for Otitis Externa. International Journal of Immunopathology and Pharmacology, 2009, 22, 299-302.	1.0	8
39	The Impact of Prulifloxacin on Vaginal Lactobacillus Microflora: An <i>In Vivo</i> Study. Journal of Chemotherapy, 2009, 21, 646-650.	0.7	10
40	<i>In vitro</i> antiviral activity of <i>Melaleuca alternifolia</i> essential oil. Letters in Applied Microbiology, 2009, 49, 806-808.	1.0	103
41	Econazole-Polycarbophil, a New Delivery System for Topical Therapy: Microbiological and Clinical Results on Vaginal Candidiasis. Journal of Chemotherapy, 2008, 20, 336-340.	0.7	4
42	In vitro antimycoplasmal activity of Melaleuca alternifolia essential oil. Journal of Antimicrobial Chemotherapy, 2006, 58, 706-707.	1.3	23
43	Topical Kanamycin: an Effective Therapeutic Option in Aerobic Vaginitis. Journal of Chemotherapy, 2006, 18, 409-414.	0.7	24
44	Antimycoplasmal Activity of Hydroxytyrosol. Antimicrobial Agents and Chemotherapy, 2004, 48, 4892-4894.	1.4	47
45	Effects on adhesiveness and hydrophobicity of sub-inhibitory concentrations of netilmicin. International Journal of Antimicrobial Agents, 2003, 22, 164-167.	1.1	21
46	Patents on streptogramin antibiotics. Expert Opinion on Therapeutic Patents, 2003, 13, 651-659.	2.4	2
47	Patents on streptogramin antibiotics therapeutics. Expert Opinion on Therapeutic Patents, 2003, 13, 651-659.	2.4	1
48	In vitro antimycoplasmal activity of oleuropein. International Journal of Antimicrobial Agents, 2002, 20, 293-296.	1.1	91
49	Combining molecular modeling with experimental methodologies: mechanism of membrane permeation and accumulation of ofloxacin. Bioorganic and Medicinal Chemistry, 2002, 10, 3871-3889.	1.4	75
50	Novel streptogramin antibiotics. Expert Opinion on Investigational Drugs, 2001, 10, 185-198.	1.9	37
51	Two New Point Mutations at A2062 Associated with Resistance to 16-Membered Macrolide Antibiotics in Mutant Strains of Mycoplasma hominis. Antimicrobial Agents and Chemotherapy, 2001, 45, 2958-2960.	1.4	37
52	Antimicrobial Nonapeptide Leucinostatin A-Dependent Effects on the Physical Properties of Phospholipid Model Membranes. Journal of Colloid and Interface Science, 2000, 226, 222-230.	5.0	39
53	Genetic basis of natural resistance to erythromycin in Mycoplasma hominis. Journal of Antimicrobial Chemotherapy, 2000, 45, 547-548.	1.3	33
54	Ofloxacin-Loaded Liposomes: In Vitro Activity and Drug Accumulation in Bacteria. Antimicrobial Agents and Chemotherapy, 2000, 44, 2458-2464.	1.4	69

#	Article	IF	CITATIONS
55	Correlation of trimethoprim and brodimoprim physicochemical and lipid membrane interaction properties with their accumulation in human neutrophils. Antimicrobial Agents and Chemotherapy, 1996, 40, 2865-2873.	1.4	18
56	Pefloxacine Mesilate- and Ofloxacin-Loaded Polyethylcyanoacrylate Nanoparticles: Characterization of the Colloidal Drug Carrier Formulation. Journal of Pharmaceutical Sciences, 1995, 84, 895-902.	1.6	97
57	Formulation parameters of fluoroquinolone-loaded liposomes and in vitro antimicrobial activity. International Journal of Pharmaceutics, 1995, 118, 65-76.	2.6	41
58	Levels of flurithromycin in female genital tissue. Antimicrobial Agents and Chemotherapy, 1995, 39, 1899-1901.	1.4	2
59	Intracellular accumulation of ofloxacin-loaded liposomes in human synovial fibroblasts. Antimicrobial Agents and Chemotherapy, 1995, 39, 1372-1375.	1.4	28
60	In-vitro antimycoplasmal activity of flurithromycin. Journal of Antimicrobial Chemotherapy, 1995, 35, 161-165.	1.3	5
61	In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922. Antimicrobial Agents and Chemotherapy, 1994, 38, 2651-2654.	1.4	7
62	Laparoscopy diagnosis of chlamydial salpingitis using a tubal cytobrush. Fertility and Sterility, 1994, 61, 181-184.	0.5	1
63	In vitro Activity of Rufloxacin against <i>Listeria monocytogenes</i> , <i>Legionella pneumophila</i> , and Chlamydia trachomatis. Chemotherapy, 1994, 40, 104-108.	0.8	6
64	Seroprevalence to some torch agents in a sicilian female population of fertile age. European Journal of Epidemiology, 1993, 9, 341-343.	2.5	12
65	In vitro antiviral activity of four isothiazole derivatives against poliovirus type 1. Antiviral Research, 1992, 19, 29-41.	1.9	7
66	In vitro activity of flurithromycin against some genital pathogens. Drugs Under Experimental and Clinical Research, 1991, 17, 175-80.	0.3	1
67	Some pharmacokinetic data on miocamycin II. Concentrations in gynaecological tissues. Drugs Under Experimental and Clinical Research, 1991, 17, 181-5.	0.3	1
68	Macrolides: present and future. An appraisal of in-vitro activity and pharmacokinetic behavior. Journal of Chemotherapy, 1991, 3 Suppl 1, 24-7.	0.7	1
69	Female genital tissue concentrations of roxithromycin. Journal of Chemotherapy, 1991, 3 Suppl 1, 30-2.	0.7	0
70	In-vitro and in-vivo activity of roxithromycin against Chlamydia trachomatis. Journal of Chemotherapy, 1991, 3 Suppl 1, 36-8.	0.7	0
71	Inhibitory effects of 3-imino-5-phenyl-3H-1,2-dithiole on poliovirus type 1 replication in vitro. Antiviral Research, 1990, 14, 267-277.	1.9	7
72	Serum IgA antibodies in HSV asymptomatic genital infections. Journal of Medical Virology, 1989, 27, 210-214.	2.5	2

#	Article	IF	CITATIONS
73	C. trachomatis detection in infertile women by using a tubal cytobrush during laparoscopy. Acta Europaea Fertilitatis, 1989, 20, 363-5.	0.0	4
74	Pharmacokinetic data and therapeutic efficacy of miocamycin: serum, urinary and prostatic levels. Therapeutic aspects in acute urethral syndrome and non-gonococcal urethritis. Journal of Chemotherapy, 1989, 1, 581-2.	0.7	0
75	Some features of miocamycin in the gynecological field: pharmacokinetic data using preoperative administration and therapeutic aspects against chlamydial infections. Journal of Chemotherapy, 1989, 1, 585-6.	0.7	2
76	Some methodological problems in the control of human mycoplasma infections. Journal of Chemotherapy, 1989, 1, 803-4.	0.7	0
77	Therapeutic considerations about psittacosis: remarks on a case of family psittacosis. Journal of Chemotherapy, 1989, 1, 915-6.	0.7	0
78	Efficacy of miocamycin in the therapy of non-specific genital infections (NSGI): non-gonococcal urethritis (NGU) and acute urethral syndrome (AUS). International Journal of Clinical Pharmacology Research, 1988, 8, 111-6.	0.4	2
79	Some pharmacokinetic data on miocamycin. I: Serum, urinary and prostatic levels. Drugs Under Experimental and Clinical Research, 1988, 14, 755-62.	0.3	1
80	Further characterization of the in vitro and in vivo activity of ciprofloxacin against mycoplasmas. Chemioterapia: International Journal of the Mediterranean Society of Chemotherapy, 1987, 6, 346-9.	0.0	0
81	Anti-mycoplasmal activity of a new macrolide: miocamycin. Chemioterapia: International Journal of the Mediterranean Society of Chemotherapy, 1987, 6, 341-5.	0.0	2
82	ENDOSYMBIONTS OF ENTOMOPATHOGENIC NEMATODES FROM SOUTH ITALY: A PHENOTYPIC STUDY. Redia, 0, , 183-188.	0.1	3